Drug intelligence / Profile preview

DWC-20141

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC-20141 is an investigational small molecule drug developed by Daewoong Pharmaceutical. Its precise mechanism of action has not been disclosed, and it is not considered to have a novel mechanism. The drug is administered orally and has been studied in healthy volunteers, including in drug-drug interaction studies with other Daewoong pipeline compounds. As of the latest available information, its global development status remains pending, and no FDA designation or approved indication has been reported[1][2][3][8].

Beyond the preview

Go deeper on DWC-20141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC-20141.

Explore the full profile